Market Overview

UPDATE: Raymond James Upgrades Becton, Dickinson & Company from Underperform to Market Perform

Share:
Related BDX
Earnings Scheduled For February 2, 2017
7 Biotech And Healthcare Picks For 2017 From Cantor Fitzgerald

In a research note published Wednesday, Raymond James upgraded Becton, Dickinson and Company (NYSE: BDX) from Underperform to Market Perform.

The firm's Lawrence Keusch noted Becton, Dickinson and Company's business has stabilized and this is reflected in the solid Q1 results.

Keusch also believes that shares of BDX will perform inline with the market citing a valuation reflecting improved fundamentals and numerous defensive qualities in its business profile, which are likely to be favored in the current equity market.

BDX's shares are currently up 0.77 percent trading around $106.71.

Latest Ratings for BDX

DateFirmActionFromTo
Jan 2017Raymond JamesDowngradesStrong BuyOutperform
Jan 2017JP MorganDowngradesOverweightNeutral
Sep 2016CitigroupDowngradesNeutralSell

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!